Dimerix Limited (AU:DXB) has released an update.
Dimerix Limited has reported a promising first interim analysis outcome from the ACTION3 Phase 3 trial of their drug DMX-200, showing better performance than placebo in reducing proteinuria in FSGS patients. The company’s financial position remains strong with a cash reserve of AU$35.2 million after successfully completing a AU$20 million institutional placement. Dimerix’s ongoing trial exhibits a robust safety profile and has been recommended to proceed without changes by the Independent Data Monitoring Committee.
For further insights into AU:DXB stock, check out TipRanks’ Stock Analysis page.
